Clinical drug

acoramidis 356 MG Oral Tablet

356 MG · Oral Tablet · oral

A form of acoramidis

acoramidis 356 MG Oral Tablet — Other cardiac preparations. INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM

acoramidis 356 MG Oral Tablet

Active ingredient

Classification

Other cardiac preparations

Drug interactions

Acoramidis has several drug interactions that may affect its metabolism and the metabolism of other drugs.

  • majorUGT inducers — decreased acoramidis exposure
  • majorstrong CYP3A inducers — decreased acoramidis exposure
  • moderatesensitive CYP2C9 substrates — increased CYP2C9 substrate concentrations

Real-world adverse events (FAERS)

Diarrhoea45Fatigue16Dizziness15Abdominal Discomfort14Blood Creatinine Increased12Nausea11Asthenia10Dyspnoea10

Indications

INDICATIONS AND USAGE ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )

Dosage

DOSAGE AND ADMINISTRATION The recommended dosage of ATTRUBY is 712 mg orally twice daily. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of ATTRUBY is 712 mg orally twice daily (with or without food). Swallow tablets whole; do not cut, crush, or chew.

Contraindications

CONTRAINDICATIONS None. None. ( 4 ) To report SUSPECTED ADVERSE REACTIONS, contact BridgeBio Pharma Inc. at 1-844-550-2246 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Mechanism of action

Mechanism of Action Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.

Indicated ICD-10 codes

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.